Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - AKCEA THERAPEUTICS, INC. | ex99_1.htm |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 5, 2018
AKCEA THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
|
001-38137
|
47-2608175
|
|
|
(Commission File No.)
|
(IRS Employer Identification No.)
|
22 Boston Wharf Rd., 9th Floor
Boston, Massachusetts 02210
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code:
(617) 207-0202
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
Emerging growth company ☑
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☑
|
Item 8.01.
|
Other Events.
|
On October 5, 2018, Akcea Therapeutics, Inc. (the “Company”),
an affiliate of Ionis Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved TEGSEDITM (inotersen) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in
adults. TEGSEDI is now approved in the U.S., the European Union and Canada. A copy of the press release is attached to this Report as Exhibit 99.1 and is incorporated by reference into
this Item 8.01.
| Item 9.01. |
Financial Statements and Exhibits.
|
(d) Exhibits
|
Exhibit No.
|
Description
|
|
|
Press Release, dated October 5, 2018, issued by the Company
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
|
Akcea Therapeutics, Inc.
|
||
|
Dated: October 5, 2018
|
By:
|
/s/ Paula Soteropoulos
|
|
Paula Soteropoulos
|
||
|
Chief Executive Officer
|
||